Lawrence Deyton

4.5k citations

36 papers · 3.5k indexed · 1 hit paper · h-index 18

Impact in

Virology top 0.2%
- HIV Research and Treatment
Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in ⓘ

Virology 10
- HIV Research and Treatment 10
Infectious Diseases 17
- HIV/AIDS drug development and treatment 13
- HIV/AIDS Research and Interventions 12

Co-authors: Judith Feinberg (3 shared papers)Louise Pedneault (1 shared paper)Bach‐Yen Nguyen (1 shared paper)Margaret A. Fischl (2 shared papers)Kathleen Squires (2 shared papers)Joseph J. Eron (2 shared papers)Judith S. Currier (2 shared papers)Scott M. Hammer (2 shared papers)
Journals: New England Journal of Medicine (4 papers)The Lancet (3 papers)AIDS (2 papers)Academic Medicine (2 papers)Clinical Infectious Diseases (1 paper)
Partner nations: United States United Kingdom India

In The Last Decade

Lawrence Deyton

32 papers receiving 3.3k citations

Hit Papers

align trajectories log scale

A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less 1997 · 2.1k citations

Peers

Countries citing papers authored by Lawrence Deyton

Since Specialization

Citations

This map shows the geographic impact of Lawrence Deyton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lawrence Deyton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lawrence Deyton more than expected).

Fields of papers citing papers by Lawrence Deyton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lawrence Deyton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lawrence Deyton. The network helps show where Lawrence Deyton may publish in the future.

Co-authors

The 25 scholars most cited alongside Lawrence Deyton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lawrence Deyton Line = papers co-authored together Lawrence Deyton links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less New England Journal of Medicine ·Scott M. Hammer, Kathleen Squires, Michael D. Hughes, Janet M. Grimes, Lisa M. Demeter, Judith S. Currier, Joseph J. Eron, Judith Feinberg, Henry H. Balfour, Lawrence Deyton, Jeffrey Chodakewitz, Margaret A. Fischl, John Phair, Louise Pedneault, Bach‐Yen Nguyen, Jon C. Cook Hit paper breakdown →	1997	2125
2	ANTI-RETROVIRAL EFFECTS OF INTERFERON-α IN AIDS-ASSOCIATED KAPOSI'S SARCOMA The Lancet ·H. Clifford Lane, Judith Feinberg, Victoria J. Davey, Lawrence Deyton, Michael Baseler, Jody Manischewitz, Henry Masur, Joseph A. Kovacs, Betsey Herpin, Robert Walker, J A Metcalf, Norman P. Salzman, Gerald V. Quinnan, A S Fauci	1988	220
3	A Comparative Trial of Didanosine or Zalcitabine after Treatment with Zidovudine in Patients with Human Immunodeficiency Virus Infection New England Journal of Medicine ·Donald I. Abrams, Anne I. Goldman, Cynthia A. Launer, Joyce A. Korvick, James D. Neaton, Lawrence R. Crane, Michael J. Grodesky, Steven Wakefield, K Muth, Sandra Kornegay, David L. Cohn, Allen Harris, Roberta Luskin‐Hawk, Norman Markowitz, James Sampson, Melanie Thompson, Lawrence Deyton	1994	150
4	AIDS-related malignant lymphoma: results of prospective treatment trials. Journal of Clinical Oncology ·Parkash S. Gill, A Levine, Mark Krailo, Mark U. Rarick, Carmen L. Loureiro, Lawrence Deyton, P Meyer, S Rasheed	1987	149
5	Reversible Cardiac Dysfunction Associated with Interferon Alfa Therapy in AIDS Patients with Kaposi's Sarcoma New England Journal of Medicine ·Lawrence Deyton, Robert Walker, Joseph A. Kovacs, Betsey Herpin, Monica Parker, Henry Masur, Anthony S. Fauci, H. Clifford Lane	1989	97
6	Cannabis Inflorescence for Medical Purposes: USP Considerations for Quality Attributes Journal of Natural Products ·Nandakumara Sarma, Andrew Waye, Mahmoud A. ElSohly, Paula N. Brown, Sytze Elzinga, Holly E. Johnson, Robin J. Marles, Jeremy E. Melanson, Ethan B. Russo, Lawrence Deyton, Christopher Hudalla, Gordon Vrdoljak, Joshua Wurzer, Ikhlas A. Khan, Nam-Cheol Kim, Gabriel I. Giancaspro	2020	77
7	Understanding the Tobacco Control Act: efforts by the US Food and Drug Administration to make tobacco-related morbidity and mortality part of the USA's past, not its future The Lancet ·Corinne G. Husten, Lawrence Deyton	2013	66
8	HIV, hepatitis C and HIV/hepatitis C virus co-infection in vulnerable populations AIDS ·Lisa I. Backus, Derek Boothroyd, Lawrence Deyton	2005	64
9	Tobacco Product Regulation — A Public Health Approach New England Journal of Medicine ·Lawrence Deyton, Joshua Sharfstein, Margaret Hamburg	2010	59
10	Considerations in choice of a clinical endpoint for AIDS clinical trials Statistics in Medicine ·James D. Neaton, Deborah Wentworth, Frank S. Rhame, Carlton Hogan, Donald I. Abrams, Lawrence Deyton	1994	57
11	The immunology case registry Journal of Clinical Epidemiology ·Lisa I. Backus, L Molé, Sophia W. Chang, Lawrence Deyton	2001	47
12	Pharmacokinetics and Tolerability of Oseltamivir Combined with Probenecid Antimicrobial Agents and Chemotherapy ·Mark Holodniy, Scott Penzak, Timothy M. Straight, Richard T. Davey, Kelvin K. Lee, Matthew Bidwell Goetz, Dennis W. Raisch, Francesca Cunningham, Emil T. Lin, Noemí Olivo, Lawrence Deyton	2008	44
13	Response of CD4 Lymphocytes and Clinical Consequences of Treatment Using ddI or ddC In Patients with Advanced HIV Infection Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology ·Anne I. Goldman, Bradley P. Carlin, Lawrence R. Crane, Cynthia A. Launer, Joyce A. Korvick, Lawrence Deyton, Donald I. Abrams	1996	43
14	Primary Prophylaxis with Pyrimethamine for Toxoplasmic Encephalitis in Patients with Advanced Human Immunodeficiency Virus Disease: Results of a Randomized Trial The Journal of Infectious Diseases ·Mark Z. Jacobson, C. Lynn Besch, Carroll Child, Richard Hafner, John P. Matts, K Muth, Deborah Wentworth, James D. Neaton, D Abrams, David Rimland, George Perez, I. H. Grant, Louis D. Saravolatz, Lawrence S. Brown, Lawrence Deyton	1994	40
15	Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis The Lancet ·Mark Z. Jacobson, Carroll Child, C. Lynn Besch, Richard Hafner, Lawrence Deyton, John P. Matts, Deborah Wentworth, K Muth	1992	30
16	Teaching Trauma-Informed Care: A Symposium for Medical Students MedEdPORTAL ·Binny Chokshi, Kimberly Walsh, Danielle G. Dooley, Olanrewaju Falusi, Lawrence Deyton, Lee Beers	2020	23
17	Relationship Between Antiretroviral Prescribing Patterns and Treatment Guidelines in Treatment-Naive HIV-1-Infected US Veterans (1992-2004) JAIDS Journal of Acquired Immune Deficiency Syndromes ·Mark Holodniy, John Hornberger, Dana Rapoport, Katherine Robertus, Thomas MaCurdy, J González López, Paul A. Volberding, Lawrence Deyton	2006	23
18	Community Planning for Pandemic Influenza: Lessons From the VA Health Care System Disaster Medicine and Public Health Preparedness ·Nicole Lurie, David J. Dausey, Troy Knighton, Melinda Moore, Sarah Zakowski, Lawrence Deyton	2008	19
19	Experience with a cross-study endpoint review committee for AIDS clinical trials AIDS ·Lisa A. Green, Frank S. Rhame, Richard W. Price, David C. Perlman, Linnea Capps, James Sampson, Lawrence Deyton, Steven Schnittman, Evelyn J. Fisher, Glenn E. Bartsch, Eric Krum, James D. Neaton	1998	16
20	Teaching Public and Population Health in Medical Education: An Evaluation Framework Academic Medicine ·Sherese B. Johnson, Malika Fair, Lisa D. Howley, Jacob Prunuske, Suzanne B. Cashman, Jan K. Carney, Yumi Shitama Jarris, Lawrence Deyton, Daniel S. Blumenthal, N. Kevin Krane, Nicholas H. Fiebach, A. Hal Strelnick, Emma Morton-Eggleston, Chloe Nickens, LaVonne Ortega	2020	15

About Lawrence Deyton

Lawrence Deyton is a scholar working on Virology, Infectious Diseases, Emergency Medical Services, Parasitology and Pharmacy, having authored 36 papers that have together received 3.5k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (13 papers), HIV/AIDS Research and Interventions (12 papers), HIV Research and Treatment (10 papers), Pneumocystis jirovecii pneumonia detection and treatment (5 papers), Smoking Behavior and Cessation (3 papers), Global Public Health Policies and Epidemiology (3 papers), Innovations in Medical Education (3 papers) and HIV-related health complications and treatments (3 papers). The work is most often cited by research in Virology (1.9k citations), Infectious Diseases (2.2k citations), Emergency Medicine (453 citations), Hepatology (236 citations) and Statistics and Probability (214 citations). Lawrence Deyton has collaborated with scholars based in United States, United Kingdom and India. Frequent co-authors include Judith Feinberg, Louise Pedneault, Bach‐Yen Nguyen, Margaret A. Fischl, Kathleen Squires, Joseph J. Eron, Judith S. Currier, Scott M. Hammer, Henry H. Balfour and Michael D. Hughes. Their work appears in journals such as New England Journal of Medicine, The Lancet, AIDS, Academic Medicine and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact